<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467934</url>
  </required_header>
  <id_info>
    <org_study_id>AAAJ0504</org_study_id>
    <nct_id>NCT01467934</nct_id>
  </id_info>
  <brief_title>FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging</brief_title>
  <official_title>FeverText: Assessing Fever Rates After Influenza and Pneumococcal Vaccination During the 2011-12 Influenza Season Using Text Messaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will prospectively assess fever rates and other associated
      vaccine adverse events in 6-23 month old patients during days 0-7 after administration of
      trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine
      (PCV13) concomitantly compared to those who receive trivalent inactivated influenza vaccine
      (TIV) or 13-valent pneumococcal conjugate vaccine (PCV13) administered non-concomitantly. The
      investigators hypothesize that fever rates will be significantly higher during the 0-1 days
      after vaccination when inactivated influenza vaccine (TIV) and 13-valent pneumococcal
      conjugate vaccine (PCV13) are given concomitantly than when TIV or PCV13 is administered
      non-concomitantly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fever &gt;= 100.4</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">530</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>Trivalent inactivated influenza vaccine</arm_group_label>
    <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV and PCV13 together</arm_group_label>
    <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
    <description>13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        6-23 months old visiting study sites
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. are 6 through 23 month olds,

          2. have a visit at a study site during the study period of Nov. 1, 2011 through March 31,
             2012,

          3. receive trivalent inactivated influenza vaccine (TIV)/13-valent pneumococcal conjugate
             vaccine (PCV13)concomitantly, trivalent inactivated influenza vaccine (TIV)/without
             13-valent pneumococcal conjugate vaccine (PCV13) or 13-valent pneumococcal conjugate
             vaccine (PCV13) without trivalent inactivated influenza vaccine (TIV)/(4) parent has a
             cell phone with text messaging capabilities; and

        (5) parent speaks English or Spanish.

        Exclusion criteria:

          1. presence of fever &gt;=100.4 at time of vaccination;

          2. administration of any antipyretic in the 6-hour period prior to vaccination

          3. stated intent to use prophylactic antipyretics at time of vaccination before the
             development of a fever;

          4. stated intention to move away from the NYC area &lt;6 month;

          5. parent only speaks a language other than English or Spanish;

          6. inability to read text messages;

          7. children who received live attenuated influenza vaccine (LAIV) this visit;

          8. children who received trivalent inactivated influenza vaccine (TIV) or 13-valent
             pneumococcal conjugate vaccine (PCV13) in the seven days prior to enrollment date

        Note: Patient may receive other vaccines in addition to trivalent inactivated influenza
        vaccine (TIV)/13-valent pneumococcal conjugate vaccine (PCV13)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Stockwell, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip LaRussa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Broder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>June 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2014</results_first_posted>
  <last_update_submitted>July 19, 2014</last_update_submitted>
  <last_update_submitted_qc>July 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Melissa Stockwell, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics and Population and Family Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trivalent Inactivated Influenza Vaccine (TIV) Alone</title>
          <description>Trivalent inactivated influenza vaccine 0.25ml IM X 1</description>
        </group>
        <group group_id="P2">
          <title>TIV and PCV13 Together</title>
          <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
        </group>
        <group group_id="P3">
          <title>13-valent Pneumococcal Conjugate Vaccine (PCV13) Alone</title>
          <description>13-valent pneumococcal conjugate vaccine (PCV13) 0.5ml IM x 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trivalent Inactivated Influenza Vaccine (TIV) Alone</title>
          <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1</description>
        </group>
        <group group_id="B2">
          <title>TIV and PCV13 Together</title>
          <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
        </group>
        <group group_id="B3">
          <title>13-valent Pneumococcal Conjugate Vaccine (PCV13) Alone</title>
          <description>13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="208"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6-11 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-23 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fever &gt;= 100.4</title>
        <time_frame>8 days</time_frame>
        <population>Participants in analysis included those for whom both day 0 and day 1 temperature data was reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent Inactivated Influenza Vaccine (TIV) Alone</title>
            <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1</description>
          </group>
          <group group_id="O2">
            <title>TIV and PCV13 Together</title>
            <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
          </group>
          <group group_id="O3">
            <title>13-valent Pneumococcal Conjugate Vaccine (PCV13) Alone</title>
            <description>13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
          </group>
        </group_list>
        <measure>
          <title>Fever &gt;= 100.4</title>
          <population>Participants in analysis included those for whom both day 0 and day 1 temperature data was reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="37.6"/>
                    <measurement group_id="O3" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>medical record review</desc>
      <group_list>
        <group group_id="E1">
          <title>Trivalent Inactivated Influenza Vaccine (TIV) Alone</title>
          <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1</description>
        </group>
        <group group_id="E2">
          <title>TIV and PCV13 Together</title>
          <description>Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
        </group>
        <group group_id="E3">
          <title>13-valent Pneumococcal Conjugate Vaccine (PCV13) Alone</title>
          <description>13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Stockwell</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-342-5732</phone>
      <email>mss2112@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

